For example, the B4GALNT2 (beta-1,4 N-acetylgalactosaminyltransferase 2) gene, the 3′ partner in the THRA (thyroid hormone receptor, alpha)-B4GALNT2 fusion, has been previously proposed as a prognostic biomarker of breast cancer [51] and is reported to be up regulated in colorectal and metastatic prostate cancer [52, 53]. This evidence concerns the gene THRA and metastatic prostate carcinoma.